Looking forward to the #JPM2023 in San Francisco next week, to share knowledge and insights from the most inspiring and passionate experts in digital health!

#JPM2023 #JPM23 | As the 41st Annual J.P. Morgan #Healthcare meeting goes on, we wanted to share with you the early highlights that caught our attention. Check out our first takeaways below and don't hesitate to contact us if you're also attending and would like to meet us!

So thankful for the J.P. Morgan invitation, science is moving fast for patients' sake. Many exciting companies mobilized to fight major health issues. #JPM2023 #JPM23 XENOTHERA

Merci Philippe gambert pour cet échange

Polyclonal antibodies we are developing in oncology are also very promising. Our drug candidates against T-cell lymphomas and solid tumors are scheduled to enter clinical trials this year.

📍 #ESMOTAT23 | Our team is very pleased to be attending this week's ESMO Targeted Anticancer Therapies Congress, the leading conference dedicated to the most promising new anticancer drugs, with a focus on early-phase clinical development 🔬 #Immunotherapy #PrecisionOncology

🇨🇳 From April 3rd to April 6th 2023, XENOTHERA will be on a mission with Business France in China. An opportunity to discuss possible collaborations and partnerships with the majors of the Chinese pharmaceutical sector. More info in our press release 👉 linkedin.com/posts/xenother…

🇺🇸 #ASCO2023 | Nous sommes ravis d'annoncer notre participation à l’ASCO. Nous publions à cette occasion deux abstracts démontrant l’intérêt de notre technologie contre les cancers. Plus d'infos dans notre communiqué de presse 👇 linkedin.com/feed/update/ur… #Oncologie #Traitement

🇺🇸 #ASCO2023 | We are closing this year's ASCO Annual Meeting, an amazing event at which we have witnessed countless groundbreaking advances in #oncology. Discover our pick of the highlights below 👇 A big thanks to ASCO for hosting this inspiring and knowledge-sharing congress.

🇨🇭#17ICML | Our XENOTHERA team is thrilled to be part of the 17th #ICML in Lugano! Huge achievements in addressing major unmet medical needs in #lymphoma, notably PTCL where XENOTHERA is developing a therapeutic candidate 🧪 International Conference on Malignant Lymphoma Odile Duvaux

[#XENONEWS 🗞] Alors que nous avançons en 2023, nous sommes heureux de partager les progrès significatifs que nous avons réalisés dans notre newsletter du mois de juillet, avec l’édito de notre Présidente Odile Duvaux 👇 izsogood.co/so/f8Ob4-Av4?l…

📢 #LymphomesT | Le LIS1, issu de notre plateforme technologique d’anticorps (GH-pAb), a prouvé son efficacité anti-lymphome T dans les études précliniques. 🔍 Plus d'informations à retrouver dans notre communiqué ⬇ izsogood.co/so/45Og4RjIL?l…